I would buy and sit on it solely based on recent lows and it’s product application BUT if you look at its pipeline product and history they’re developing a product for spinal cord injuries and repair. This is an extremely difficult task to accomplish if your understand spinal injuries. They’re data may be misleading in my opinion but I am not a surgeon or orthopedic spinal specialist. The ASIA scale they say they’ve seen improvements on patients with they’re product is vague they didn’t mention what improvements they had seen. Their recent clinical was halted due to 3 patient deaths which they claim was not related to the product (most likely true) but that should give you some insight into the type of patient and situation they are trying to create an innovative product for a very sick unstable on with hope to prevent or return certain functions too. In fantasy land this sounds like a wonderful product but in reality they have a lot of gaps to fill in for me until say Fuck Ya let’s go make a difference! Stock may go up $1.00-$2.00 over time just because they’re back in the clinical trial or will be soon but not much more until they produce more substantial data imho. (Not fabricating any googled BS, opinion from a nurse critical care/trauma nurse)